Nav: Home

Analysis from the MYSTIC Trial

September 08, 2019

Barcelona--The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized. Dr. N. Rizvi from Columbia University Medical Center in New York today presented an update from the Phase III MYSTIC study that showed poorer outcomes across treatment arms in patients with metastatic non-small cell lung cancer and mutations in STK11 or KEAP1 genes compared with those without the corresponding mutations. In patients receiving durvalumab with tremelimumab, ARID1Am was associated with survival benefits compared with ARID1Awt.

Rizvi presented his data today at the IASLC 2019 Word Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

The MYSTIC trial is a randomized, open-label, multi-center, global Phase III trial of durvalumab monotherapy or durvalumab in combination with tremelimumab versus chemotherapy in the 1st-line treatment of patients with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type, locally-advanced or metastatic non-small cell lung cancer. The trial was conducted at 203 sites in 17 countries. Previously, according to research published in the American Association of Cancer Research, blood tumor mutational burden, at various thresholds from greater to or equal to 12 mut/Mb to ?20 mut/Mb, has been associated with improved overall survival with first-line durvalumab with or without tremelimumab versus chemotherapy.

In the current exploratory analysis, researchers obtained circulating tumor DNA from baseline plasma specimens from 1003 patients which was then profiled using the GuardantOMNI platform. Survival outcomes were analyzed in those with (designation with m) and without (wt) non-synonymous somatic mutations.

In the mutation-evaluable population (n=943), STK11 mutation, KEAP1 mutation, and ARID1A mutation frequencies were 16 percent, 18 percent and 12 percent, respectively (19 percent, 20 percent, and 11 percent [nonsquamous]; 7 percent, 13 percent, and 15 percent [squamous]).

Across treatment arms, patients with STK11m or KEAP1m had a shorter median overall survival than patients with STK11wt or KEAP1wt metastatic NSCLC. In the durvalumab + tremelimumab arm, patients with ARID1A mutations had a longer median overall survival rate than patients with ARID1A without mNSCLC.
-end-
About the WCLC:

The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2019.iaslc.org.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.

International Association for the Study of Lung Cancer

Related Lung Cancer Articles:

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
Air pollution is associated with cancer mortality beyond lung cancer
A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
More Lung Cancer News and Lung Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.